Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276

Watchlist Manager
Jiangsu Hengrui Pharmaceuticals Co Ltd Logo
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Watchlist
Price: 62.51 CNY 1.44%
Market Cap: 398.8B CNY

Jiangsu Hengrui Pharmaceuticals Co Ltd
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Jiangsu Hengrui Pharmaceuticals Co Ltd
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
EPS (Diluted)
¥1
CAGR 3-Years
26%
CAGR 5-Years
4%
CAGR 10-Years
14%
C
CSPC Pharmaceutical Group Ltd
HKEX:1093
EPS (Diluted)
¥0
CAGR 3-Years
-10%
CAGR 5-Years
-1%
CAGR 10-Years
5%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
EPS (Diluted)
¥0
CAGR 3-Years
20%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
EPS (Diluted)
¥4
CAGR 3-Years
-1%
CAGR 5-Years
9%
CAGR 10-Years
17%
Yunnan Baiyao Group Co Ltd
SZSE:000538
EPS (Diluted)
¥2
CAGR 3-Years
25%
CAGR 5-Years
-5%
CAGR 10-Years
1%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
EPS (Diluted)
¥9
CAGR 3-Years
N/A
CAGR 5-Years
241%
CAGR 10-Years
N/A
No Stocks Found

Jiangsu Hengrui Pharmaceuticals Co Ltd
Glance View

Nestled in the throbbing economic heart of China's Jiangsu province, Jiangsu Hengrui Pharmaceuticals Co Ltd has carved a niche as a formidable player in the global pharmaceutical landscape. Established in 1970, this company has evolved from its humble beginnings into a powerhouse known for its relentless focus on research and development, a keystone in its operational strategy. Hengrui has built a diverse portfolio of products, primarily focusing on oncological, cardiovascular, and anti-diabetic therapeutics. The company leverages its state-of-the-art R&D facilities and a team of top-tier scientists to innovate and advance new treatment solutions, which are then patented to ensure exclusivity and competitive market positioning. In addition to its robust R&D-driven pipeline, Hengrui thrives through strategic collaborations and international partnerships that enhance its market reach and deepen its competitive moat. Revenue generation springs from a dual-engine model: sales of proprietary drugs and a burgeoning generic drug segment that ensures steady cash flow. Furthermore, Hengrui's ability to navigate the intricate regulatory landscapes of different countries enables it to market its innovative therapies globally, thus broadening its revenue streams. With an eye toward sustainable growth, the company continually reinvests a significant portion of its profits back into R&D, sustaining its cycle of innovation and market leadership, while also playing a vital role in meeting global healthcare needs.

Intrinsic Value
48.12 CNY
Overvaluation 23%
Intrinsic Value
Price

See Also

What is Jiangsu Hengrui Pharmaceuticals Co Ltd's EPS (Diluted)?
EPS (Diluted)
1.1 CNY

Based on the financial report for Sep 30, 2025, Jiangsu Hengrui Pharmaceuticals Co Ltd's EPS (Diluted) amounts to 1.1 CNY.

What is Jiangsu Hengrui Pharmaceuticals Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
14%

Over the last year, the EPS (Diluted) growth was 31%. The average annual EPS (Diluted) growth rates for Jiangsu Hengrui Pharmaceuticals Co Ltd have been 26% over the past three years , 4% over the past five years , and 14% over the past ten years .

Back to Top